source
- Atsena reports early efficacy signals for gene therapy ATSN-201 in X-linked retinoschisis trialAtsena Therapeutics presented data from the early parts of its Lighthouse gene therapy trial for X-linked retinoschisis (XLRS) at the American Academy of Ophthalmology meeting. The trial administe…
- Stryker appoints Spencer Stiles as CEO, Kevin Lobo to become Executive ChairStryker announced a leadership change, naming Spencer Stiles as the new chief executive officer. Stiles, who has been president and COO, will also join the board. Kevin Lobo, who has led the compa…